CORDIS · 260572 · FP7
ABC Targeting Multidrug Resistant Cancer
Coordinator: HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT (HU)
Despite considerable advances in drug discovery, resistance to anticancer chemotherapy confounds the effective treatment of patients. Cancer cells can acquire broad cross-resistance to mechanistically and structurally unrelated drugs. P-glycoprotein (Pgp) actively extrudes many types of drugs from cancer cells, thereby conferring resistance to those agents. The central tenet of my work is that Pgp, a universally accepted biomarker of drug resistance, should in addition be considered as a molecular target of multidrug-resistant (MDR) cancer cells. Successful targeting of MDR cells would reduce…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €1.5M awarded to the consortium. The project runs over approximately 5 years from 2012-01-01 to 2016-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from HU
see all →- HCEMM — Establishing the Hungarian Center of Excellence for Molecular Medicine in partnership with EMBL739593 · H2020 · €15.0M
- EPIC — Centre of Excellence in Production Informatics and Control739592 · H2020 · €10.9M
- DYNASNET — Dynamics and Structure of Networks810115 · H2020 · €9.3M
- DALIA — Danube Region Water Lighthouse Action101094070 · HORIZON · €8.5M
- DETERMINISTIC6G — DETERMINISTIC E2E COMMUNICATION WITH 6G101096504 · HORIZON · €5.5M
- MOMENTUM PPDF — Momentum Premium Postdoctoral fellowship101179854 · HORIZON · €5.0M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the ERC-SG funding scheme.
- What is the EU contribution?
- The European Commission contributes €1.5M toward a total project budget of €1.5M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT (HU).
- What is the project timeline?
- The project runs from 2012-01-01 to 2016-12-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 260572.